| Literature DB >> 22546414 |
Carsten Brauer1, Isabel Hennig-Pauka, Doris Hoeltig, Falk F R Buettner, Martin Beyerbach, Hagen Gasse, Gerald-F Gerlach, Karl-H Waldmann.
Abstract
BACKGROUND: In pigs, diseases of the respiratory tract like pleuropneumonia due to Actinobacillus pleuropneumoniae (App) infection have led to high economic losses for decades. Further research on disease pathogenesis, pathogen-host-interactions and new prophylactic and therapeutic approaches are needed. In most studies, a large number of experimental animals are required to assess lung alterations at different stages of the disease. In order to reduce the required number of animals but nevertheless gather information on the nature and extent of lung alterations in living pigs, a computed tomographic scoring system for quantifying gross pathological findings was developed. In this study, five healthy pigs served as control animals while 24 pigs were infected with App, the causative agent of pleuropneumonia in pigs, in an established model for respiratory tract disease.Entities:
Mesh:
Year: 2012 PMID: 22546414 PMCID: PMC3537595 DOI: 10.1186/1746-6148-8-47
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
List of individual respiratory disease scores in the control and challenge group
| | |||||||||
| control group | 1 | 0.00 | 0.00 | 0.00 | 0.00 | 0.30 | 0.50 | 0.00 | − |
| 2 | 0.00 | 0.21 | 2.00 | 1.00 | 0.72 | 0.10 | 7.04 | − | |
| 3 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 | 0.20 | 3.57 | − | |
| 4 | 0.00 | 0.00 | 1.00 | 1.00 | 0.60 | 0.70 | 0.00 | − | |
| 5 | 1.30 | 0.29 | 3.00 | 3.00 | 0.53 | 0.30 | 3.57 | − | |
| median | 0.00 | 0.00 | 1.00 | 1.00 | 0.53 | 0.30 | 3.57 | | |
| mean | 0.26 | 0.10 | 1.20 | 1.00 | 0.53 | 0.36 | 2.84 | | |
| SD | 0.58 | 0.14 | 1.30 | 1.22 | 0.15 | 0.24 | 2.95 | | |
| challenge group | 6 | 0.00 | 0.00 | 1.00 | 2.00 | 0.40 | 1.30 | 0.00 | − |
| 7 | 0.00 | 0.00 | 3.00 | 2.00 | 0.90 | 1.00 | 0.00 | − | |
| 8 | 1.10 | 1.10 | 16.00 | 16.00 | 3.07 | 0.81 | 6.32 | + | |
| 9 | 5.20 | | 36.00 | | 19.10 | | 31.43 | + | |
| 10 | 6.92 | | 32.00 | | 26.90 | | 20.00 | + | |
| 11 | 2.70 | 1.60 | 12.00 | 14.00 | 2.60 | 2.06 | 4.39 | + | |
| 12 | 2.97 | 2.21 | 15.00 | 12.00 | 2.80 | 1.03 | 6.35 | + | |
| 13 | 3.21 | 2.23 | 21.00 | 25.00 | 2.80 | 0.89 | 12.33 | + | |
| 14 | 0.00 | 0.00 | 2.00 | 2.00 | 0.60 | 0.60 | 0.00 | − | |
| 15 | 0.00 | 0.23 | 4.00 | 1.00 | 1.33 | 0.70 | 0.00 | − | |
| 16 | 1.34 | 1.07 | 12.00 | 11.00 | 2.26 | 0.73 | 5.40 | + | |
| 17 | 1.35 | 0.24 | 5.00 | 10.00 | 1.12 | 0.93 | 1.84 | + | |
| 18 | 2.05 | 3.71 | 26.00 | 23.00 | 1.96 | 2.98 | 21.65 | + | |
| 19 | 2.38 | 1.21 | 24.00 | 22.00 | 1.36 | 2.81 | 3.42 | + | |
| 20 | 2.45 | 1.39 | 13.00 | 10.00 | 1.89 | 0.70 | 3.00 | + | |
| 21 | 2.80 | 1.98 | 14.00 | 4.00 | 1.63 | 1.03 | 5.13 | + | |
| 22 | 0.00 | 0.00 | 10.00 | 12.00 | 0.60 | 1.90 | 0.00 | − | |
| 23 | 0.88 | 1.48 | 4.00 | 7.00 | 1.70 | 2.27 | 2.63 | + | |
| 24 | 1.23 | 0.00 | 4.00 | 8.00 | 0.50 | 1.80 | 0.00 | + | |
| 25 | 1.34 | 0.61 | 9.00 | 8.00 | 0.90 | 2.10 | 1.60 | + | |
| 26 | 2.15 | 1.79 | 26.00 | 15.00 | 2.57 | 1.87 | 8.46 | + | |
| 27 | 3.34 | 1.39 | 7.00 | 7.00 | 2.07 | 1.90 | 5.20 | + | |
| 28 | 0.30 | 0.00 | 10.00 | 15.00 | 0.70 | 1.60 | 0.00 | + | |
| 29 | 0.00 | 0.00 | 10.00 | 9.00 | 0.90 | 1.70 | 0.00 | − | |
| mean | 1.82 | 1.01 | 13.17 | 10.68 | 3.36 | 1.49 | 5.80 | | |
| SD | 1.75 | 1.00 | 9.73 | 6.81 | 6.21 | 0.70 | 8.05 | ||
*Quantification of clinical signs by scoring system of Höltig et al. (2008). Day 7: not affected 0–0.7, slightly affected 0.71–7.13, moderately affected 7.14–13.56, severely affected >13.56. Day 21: not affected 0–2, slightly affected 2.01–34.70, moderately affected 34.71–67.3, severely affected >67.3.
day 3 post challenge (euthanized on day 3 post challenge), day 1 post challenge (euthanized on day 1 post challenge), SD standard deviation.
Evaluation of digital radiographic findings
| Heart shadow/visible diaphragmatic shadow | 0 |
| No increased tissue density around bronchi | 0 |
| No shading of the lung tissue | 0 |
| Heart shadow/diaphragmatic shadow visible, but superimposed by diffuse opacities | 1 |
| Mild increase in tissue density around bronchi | 1 |
| Mild diffuse shading of the lung tissue | 1 |
| Heart shadow/diaphragmatic shadow not visible | 2 |
| Severe increase in tissue density around bronchi | 2 |
| Severe diffuse shading of the lung tissue | 2 |
| Well-defined areas of high density | 3 |
Figure 1Digital radiography of the thorax on day 21 post challenge. (a) dorso-ventral view, (b) lateral view, left side, (c) lateral view, right side Arrows show focal lesions.
Classification of disease severity using radiographic, lung lesion and CT scores
| CT score on day 7 post challenge | radiographic score* on day 7 post challenge | ||||
| not affected 0–4 | slightly affected 5–15 | moderately affected 16–26 | severely affected > 26 | Total | |
| severely affected (≥2.23) | 0 | 5 (17. 2%) | 2 (6.9%) | 2 (6.9%) | 9 (31.0%) |
| moderately affected (1.71–2.22) | 0 | 0 | 2 (6.9%) | 0 | 2 (6.9%) |
| slightly affected (0.24–1.70) | 3 (10.3%) | 4 (13.8%) | 1 (3.5%) | 0 | 8 (27.6%) |
| not affected (0–0.23) | 8 (27.6%) | 2 (6. 9%) | 0 | 0 | 10 (34.5%) |
| Total | 11 (37.9%) | 11 (37.9%) | 5 (17.3%) | 2 (6.9%) | 29 (100.00%) |
| CT score on day 21 post challenge | radiographic score* on day 21 post challenge | ||||
| not affected 0–4 | slightly affected 5–15 | moderately affected 16–26 | severely affected > 26 | Total | |
| severely affected (≥ 2.23) | 0 | 0 | 2 (7.4%) | 0 | 2 (7.4%) |
| moderately affected (1.71–2.22) | 1 (3.7%) | 2 (7.4%) | 0 | 0 | 3 (11.1%) |
| slightly affected (0.24–1.70) | 1 (3.7%) | 7 (26.0%) | 2 (7.4%) | 0 | 10 (37.1%) |
| not affected (0–0.23) | 8 (29.6%) | 4 (14.8%) | 0 | 0 | 12 (44.4%) |
| Total | 10 (37.0%) | 13 (48.2%) | 4 (14.8%) | 0 | 27 (100.00%) |
| CT score on day 21 post challenge | lung lesion score** on day 21 post challenge | ||||
| not affected 0 | slightly affected 0.1–5.0 | moderately affected 5.1–10.0 | severely affected > 10 | Total | |
| severely affected (≥ 2.23) | 0 | 0 | 0 | 4 (13.8%) | 4 (13.8%) |
| moderately affected (1.71–2.22) | 0 | 0 | 3 (10.4%) | 0 | 3 (10.4%) |
| slightly affected (0.24–1.70) | 0 | 7b (24.1%) | 3 (10.3%) | 0 | 10 (34.4%) |
| not affected (0–0.23) | 10a (34.5%) | 1b (3.5%) | 1b (3.4%) | 0 | 12 (41.4%) |
| Total | 10 (34.5%) | 8 (27.6%) | 7 (24.1%) | 4 (13.8%) | 29 (100.0%) |
| radiographic score* on day 21 post challenge | lung lesion score** on day 21 post challenge | ||||
| not affected 0 | slightly affected 0.1–5.0 | moderately affected 5.1–10.0 | severely affected > 10 | Total | |
| severely affected>26 | 0 | 0 | 0 | 2 (6.9%) | 2 (6.9%) |
| moderately affected16–26 | 0 | 1 (3.5%) | 1 (3.5%) | 2 (6.9%) | 4 (13.8%) |
| slightly affected5–15 | 4 (13.8%) | 5b (17.2%) | 4 (13.8%) | 0 | 13 (44.8%) |
| not affected0–4 | 6a (20.7%) | 2b (6.9%) | 2b (6.9%) | 0 | 10 (34.5%) |
| Total | 10 (34.5%) | 8 (27.6%) | 7 (24.1%) | 4 (13.8%) | 29 (100.00%) |
*[[21]],**[[22]].
aincluding two control pigs, bincluding one control pig.
Figure 2CT-sectional image. (a) of the thorax of a pig at the level of the 7th thoracic vertebra on day 21 post-challenge, sternal recumbent position, lung window (W:1500HU/L:-600HU), (1) liver, (2) hyperdense, focal consolidation in the right diaphragmatic lung lobe; (b) of the thorax of a pig at the level of the 8th thoracic vertebra on day 21 post-challenge, sternal recumbent position, lung window (W:1500HU/L:-600HU), (1) liver. Arrows show ground-glass opacities.
Figure 3Lung changes caused by (a and b) on day 21 post challenge. Arrows show abscess-like nodules encapsulated in connective tissue.